The realisation that NF- kappaB activity is regulated by kinases and ubiquitin modifying enzymes presents multiple opportunities for therapeutic intervention. In addition to highlights from basic research, results from clinical trials using IKK and other NF- kappaB inhibitors are expected to be presented at this meeting.